T. J. Matthews

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

McElrath, M J, Corey, L, Greenberg, P D, Matthews, T J, Montefiori, D C, Rowen, L, ...

With efforts underway to develop a preventive human immunodeficiency virus type 1 (HIV-1) vaccine, it remains unclear which immune responses are sufficient to protect against infection and whether...

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Wild, C T, Shugars, D C, Greenwell, T K, McDanal, C B, Matthews, T J

To define the role of the human immunodeficiency virus type 1 (HIV-1) envelope proteins in virus infection, a series of peptides were synthesized based on various regions of the HIV-1 transmembrane...

Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4.

Ivey-Hoyle, M, Culp, J S, Chaikin, M A, Hellmig, B D, Matthews, T J, Sweet, R W, ...

The envelope glycoprotein gp120 of primate immunodeficiency viruses initiates viral attachment to CD4+ cells by binding to the CD4 antigen on host cell surfaces. However, among different CD4+ cell...

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

Gorse, G J, Patel, G B, Newman, F K, Belshe, R B, Berman, P W, Gregory, T J, ...

The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines the bind to oligomeric native and monomeric recombinant HIV-1 envelope...

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.

Chen, C H, Matthews, T J, McDanal, C B, Bolognesi, D P, Greenberg, M L

We have previously reported that synthetic peptides representing the leucine zipper domain (DP107) and a second putative helical domain (DP178) of human immunodeficiency virus type 1 (HIV-1) gp41...

Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Shugars, D C, Wild, C T, Greenwell, T K, Matthews, T J

Envelope oligomerization is thought to serve several crucial functions during the life cycle of human immunodeficiency virus type 1 (HIV-1). We recently reported that virus entry requires coiled-coil...

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Robert-Guroff, M, Aldrich, K, Muldoon, R, Stern, T L, Bansal, G P, Matthews, T J, ...

In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 (HIV-1) isolates by HIV-2- and simian immunodeficiency virus (SIV)-positive sera, extensive...

Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.

Rovinski, B, Haynes, J R, Cao, S X, James, O, Sia, C, Zolla-Pazner, S, ...

Noninfectious human immunodeficiency virus type 1 (HIV-1) viruslike particles containing chimeric envelope glycoproteins were expressed in mammalian cells by using inducible promoters. We engineered...

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.

Berman, P W, Matthews, T J, Riddle, L, Champe, M, Hobbs, M R, Nakamura, G R, ...

Vaccines prepared from the envelope glycoprotein, gp120, of the common laboratory isolate of human immunodeficiency virus type 1 (HIV-1) (IIIB/LAV-1) elicit antibodies that neutralize the homologous...

Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages.

Shadduck, P P, Weinberg, J B, Haney, A F, Bartlett, J A, Langlois, A J, Bolognesi, D P, ...

The influence of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of freshly isolated normal human peritoneal macrophages and blood monocytes was examined. Each of...

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Skinner, M A, Langlois, A J, McDanal, C B, McDougal, J S, Bolognesi, D P, Matthews, T J

Animals immunized with the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally...

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Palker, T J, Clark, M E, Langlois, A J, Matthews, T J, Weinhold, K J, Randall, R R, ...

A synthetic peptide (SP-10-IIIB) with an amino acid sequence [Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Arg-Ile-Gln-Arg-Gly-Pro -Pro-Gly-(Tyr); amino acids 303-321] from the human...

Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain.

Richardson, N E, Brown, N R, Hussey, R E, Vaid, A, Matthews, T J, Bolognesi, D P, ...

The external segment of the T4 (CD4) glycoprotein functions as the T-cell surface receptor for human immunodeficiency virus by binding the major viral coat protein (gp120) with relatively high...

Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

Matthews, T J, Weinhold, K J, Lyerly, H K, Langlois, A J, Wigzell, H, Bolognesi, D P

Interactions between retroviruses associated with acquired immunodeficiency syndrome and their receptors on lymphocytes represent the initial steps in the process of infection and are also involved...

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.

Palker, T J, Matthews, T J, Clark, M E, Cianciolo, G J, Randall, R R, Langlois, A J, ...

A highly immunogenic epitope from a conserved COOH-terminal region of the human immunodeficiency virus (HIV) gp120 envelope protein has been identified with antisera from HIV-seropositive subjects...

Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

Lyerly, H K, Matthews, T J, Langlois, A J, Bolognesi, D P, Weinhold, K J

The lymphocyte differentiation antigen CD4 serves as a receptor for human retroviruses associated with acquired immunodeficiency syndrome (AIDS) through its interaction with the major envelope virion...

Evidence of ambiguous processing and selective degradation in the noncapsid proteins of rhinovirus 1A.

McLean, C, Matthews, T J, Rueckert, R R

Pulse-chase kinetics and extensive pactamycin mapping studies show that the translation of rhinovirus 1A proceeds in the order: initiate-P1-S-P2-terminate, where P1 is the precursor to the capsid...

Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.

Robey, W G, Arthur, L O, Matthews, T J, Langlois, A, Copeland, T D, Lerche, N W, ...

This study initiates an effort to develop a safe vaccine against the acquired immunodeficiency syndrome (AIDS) that is caused by infection with a retrovirus designated human immunodeficiency virus...

Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Matthews, T J, Langlois, A J, Robey, W G, Chang, N T, Gallo, R C, Fischinger, P J, ...

By analogy to other retroviruses, the major envelope glycoprotein, gp120, of human T-lymphotropic virus type III (HTLV-III) is a probable target for neutralizing antibody. This antigen has been...

Comparison of the use of antibodies to alpha smooth muscle actin and desmin in pulmonary lymphangioleiomyomatosis.

Matthews, T J, Hornall, D, Sheppard, M N

To establish if antibodies to alpha smooth muscle actin (ASMA) are better than desmin as a tumour marker in pulmonary lymphangioleiomyomatosis both antisera were applied to five cases. ASMA strongly...

Leiomyosarcoma of soft tissue and pulmonary metastasis, both with osteoclast-like giant cells.

Matthews, T J, Fisher, C

A case is described of leiomyosarcoma with osteoclast-like giant cells in soft tissues which metastasised to the lung. The secondary tumour also contained abundant osteoclast-like giant cells, which...

Sexual reinforcement in the female rat.

Matthews, T J, Grigore, M, Tang, L, Doat, M, Kow, L M, Pfaff, D W

Sexual reinforcement in the female rat was studied in a preparation that allowed continuous operant responding for access to a male rat leading to intromission. Experiment 1 used a high operant level...

Selective sensitivity of schedule-induced activity to an operant suppression contingency.

Allan, R W, Matthews, T J

The sensitivity of pigeons' schedule-induced activity to operant consequences was studied in two experiments. During a 30-s interval between food presentations, a keylight stimulus brightened...

Effects of d-amphetamine, diazepam, and pentobarbital on the schedule-controlled pecking and locomotor activity of pigeons.

Bordi, F, Matthews, T J

Pigeons were trained on a variant of the autoshaping procedure devised by Matthews and Lerer (1987) in which a keylight stimulus ramp of increasing brightness signaled the passing of a 30-s interfood...

"Turning back the clock" on serial-stimulus sign tracking.

Allan, R W, Matthews, T J

Two experiments examined the effects of a negative (setback) response contingency on key pecking engendered by a changing light-intensity stimulus clock (ramp stimulus) signaling fixed-time 30-s food...

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

McElrath, M J, Corey, L, Greenberg, P D, Matthews, T J, Montefiori, D C, Rowen, L, ...

With efforts underway to develop a preventive human immunodeficiency virus type 1 (HIV-1) vaccine, it remains unclear which immune responses are sufficient to protect against infection and whether...

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Wild, C T, Shugars, D C, Greenwell, T K, McDanal, C B, Matthews, T J

To define the role of the human immunodeficiency virus type 1 (HIV-1) envelope proteins in virus infection, a series of peptides were synthesized based on various regions of the HIV-1 transmembrane...

Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4.

Ivey-Hoyle, M, Culp, J S, Chaikin, M A, Hellmig, B D, Matthews, T J, Sweet, R W, ...

The envelope glycoprotein gp120 of primate immunodeficiency viruses initiates viral attachment to CD4+ cells by binding to the CD4 antigen on host cell surfaces. However, among different CD4+ cell...

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

Gorse, G J, Patel, G B, Newman, F K, Belshe, R B, Berman, P W, Gregory, T J, ...

The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines the bind to oligomeric native and monomeric recombinant HIV-1 envelope...

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.

Chen, C H, Matthews, T J, McDanal, C B, Bolognesi, D P, Greenberg, M L

We have previously reported that synthetic peptides representing the leucine zipper domain (DP107) and a second putative helical domain (DP178) of human immunodeficiency virus type 1 (HIV-1) gp41...

Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Shugars, D C, Wild, C T, Greenwell, T K, Matthews, T J

Envelope oligomerization is thought to serve several crucial functions during the life cycle of human immunodeficiency virus type 1 (HIV-1). We recently reported that virus entry requires coiled-coil...

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Robert-Guroff, M, Aldrich, K, Muldoon, R, Stern, T L, Bansal, G P, Matthews, T J, ...

In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 (HIV-1) isolates by HIV-2- and simian immunodeficiency virus (SIV)-positive sera, extensive...

Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.

Rovinski, B, Haynes, J R, Cao, S X, James, O, Sia, C, Zolla-Pazner, S, ...

Noninfectious human immunodeficiency virus type 1 (HIV-1) viruslike particles containing chimeric envelope glycoproteins were expressed in mammalian cells by using inducible promoters. We engineered...

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.

Berman, P W, Matthews, T J, Riddle, L, Champe, M, Hobbs, M R, Nakamura, G R, ...

Vaccines prepared from the envelope glycoprotein, gp120, of the common laboratory isolate of human immunodeficiency virus type 1 (HIV-1) (IIIB/LAV-1) elicit antibodies that neutralize the homologous...

Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages.

Shadduck, P P, Weinberg, J B, Haney, A F, Bartlett, J A, Langlois, A J, Bolognesi, D P, ...

The influence of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of freshly isolated normal human peritoneal macrophages and blood monocytes was examined. Each of...

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Skinner, M A, Langlois, A J, McDanal, C B, McDougal, J S, Bolognesi, D P, Matthews, T J

Animals immunized with the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally...

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Palker, T J, Clark, M E, Langlois, A J, Matthews, T J, Weinhold, K J, Randall, R R, ...

A synthetic peptide (SP-10-IIIB) with an amino acid sequence [Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Arg-Ile-Gln-Arg-Gly-Pro -Pro-Gly-(Tyr); amino acids 303-321] from the human...

Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain.

Richardson, N E, Brown, N R, Hussey, R E, Vaid, A, Matthews, T J, Bolognesi, D P, ...

The external segment of the T4 (CD4) glycoprotein functions as the T-cell surface receptor for human immunodeficiency virus by binding the major viral coat protein (gp120) with relatively high...

Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

Matthews, T J, Weinhold, K J, Lyerly, H K, Langlois, A J, Wigzell, H, Bolognesi, D P

Interactions between retroviruses associated with acquired immunodeficiency syndrome and their receptors on lymphocytes represent the initial steps in the process of infection and are also involved...

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.

Palker, T J, Matthews, T J, Clark, M E, Cianciolo, G J, Randall, R R, Langlois, A J, ...

A highly immunogenic epitope from a conserved COOH-terminal region of the human immunodeficiency virus (HIV) gp120 envelope protein has been identified with antisera from HIV-seropositive subjects...

Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

Lyerly, H K, Matthews, T J, Langlois, A J, Bolognesi, D P, Weinhold, K J

The lymphocyte differentiation antigen CD4 serves as a receptor for human retroviruses associated with acquired immunodeficiency syndrome (AIDS) through its interaction with the major envelope virion...

Evidence of ambiguous processing and selective degradation in the noncapsid proteins of rhinovirus 1A.

McLean, C, Matthews, T J, Rueckert, R R

Pulse-chase kinetics and extensive pactamycin mapping studies show that the translation of rhinovirus 1A proceeds in the order: initiate-P1-S-P2-terminate, where P1 is the precursor to the capsid...

Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.

Robey, W G, Arthur, L O, Matthews, T J, Langlois, A, Copeland, T D, Lerche, N W, ...

This study initiates an effort to develop a safe vaccine against the acquired immunodeficiency syndrome (AIDS) that is caused by infection with a retrovirus designated human immunodeficiency virus...

Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Matthews, T J, Langlois, A J, Robey, W G, Chang, N T, Gallo, R C, Fischinger, P J, ...

By analogy to other retroviruses, the major envelope glycoprotein, gp120, of human T-lymphotropic virus type III (HTLV-III) is a probable target for neutralizing antibody. This antigen has been...

Comparison of the use of antibodies to alpha smooth muscle actin and desmin in pulmonary lymphangioleiomyomatosis.

Matthews, T J, Hornall, D, Sheppard, M N

To establish if antibodies to alpha smooth muscle actin (ASMA) are better than desmin as a tumour marker in pulmonary lymphangioleiomyomatosis both antisera were applied to five cases. ASMA strongly...

Leiomyosarcoma of soft tissue and pulmonary metastasis, both with osteoclast-like giant cells.

Matthews, T J, Fisher, C

A case is described of leiomyosarcoma with osteoclast-like giant cells in soft tissues which metastasised to the lung. The secondary tumour also contained abundant osteoclast-like giant cells, which...

Sexual reinforcement in the female rat.

Matthews, T J, Grigore, M, Tang, L, Doat, M, Kow, L M, Pfaff, D W

Sexual reinforcement in the female rat was studied in a preparation that allowed continuous operant responding for access to a male rat leading to intromission. Experiment 1 used a high operant level...

Selective sensitivity of schedule-induced activity to an operant suppression contingency.

Allan, R W, Matthews, T J

The sensitivity of pigeons' schedule-induced activity to operant consequences was studied in two experiments. During a 30-s interval between food presentations, a keylight stimulus brightened...

Effects of d-amphetamine, diazepam, and pentobarbital on the schedule-controlled pecking and locomotor activity of pigeons.

Bordi, F, Matthews, T J

Pigeons were trained on a variant of the autoshaping procedure devised by Matthews and Lerer (1987) in which a keylight stimulus ramp of increasing brightness signaled the passing of a 30-s interfood...

"Turning back the clock" on serial-stimulus sign tracking.

Allan, R W, Matthews, T J

Two experiments examined the effects of a negative (setback) response contingency on key pecking engendered by a changing light-intensity stimulus clock (ramp stimulus) signaling fixed-time 30-s food...

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules

Gorse, G. J., Schwartz, D. H., Graham, B. S., Matthews, T. J., Stablein, D. M., Frey, S. E., ...

The purpose of this randomized, double-blind study was to test the safety and immunogenicity of an HIV-1LAI recombinant gp160 (rgp160) vaccine in healthy, uninfected volunteers using accelerated...